Immunicum AB: Immunicum to Participate in the New Cancer Research Consortium Oncode-PACT
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced that the company will participate in the public-private partnership Oncode-PACT, which will be supported by the National Growth Fund, an initiative of the Dutch Ministry of Economic Affairs and Climate Policy and the Ministry of Finance.
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer drugs. This has just been announced during the press conference by Jeroen Dijsselbloem, chairman of the National Growth Fund Committee. With this investment, Oncode-PACT will develop valuable drug candidates faster and cheaper and thus bring them to patients sooner. This will improve the quality of life of cancer patients while strengthening the future economic earning capacity of the Netherlands.
The development of a medicine takes on average 10 to 15 years, from the first scientific insights obtained in the laboratory, to the moment that patients can have access to it. However, it is a common occurrence that a drug candidate is not effective enough, or it does not reach the right patient for other reasons during this lengthy process. Low success rates due to often late failures in drug development come at the price of high investments that ultimately do not lead to new drugs for patients. The current development process of anti-cancer drugs is therefore expensive, takes too long, and usually works only for a subset of the intended target patients. Oncode-PACT aims to provide solutions to these problems.
Patients in the lab
Oncode-PACT has the ambition to develop new demonstrably effective cancer drugs faster and more cost-effectively. The medical need is urgent, because cancer remains the number one cause of death in our country. Alain Kummer, Managing Director Oncode Institute and Chairman of Oncode-PACT, explains: “Oncode-PACT places the patient at the center of the entire drug development chain. In the current situation, the preclinical development process is still insufficiently connected with the clinical practice, and we focus on the patient too late in the drug development process. By deploying patient data and tissues from patients early in the development process – for example organoid technology and artificial intelligence – it is possible to assess whether a potential drug could be effective and safe much earlier in the process than is currently possible, and with greater certainty.”
This way, Oncode-PACT brings the patient into the lab. This reduces the chance that drug candidates drop out during late-stage clinical studies. With the approach envisioned by Oncode-PACT, it will be clearer before the start of clinical research, in which patient group the greatest effectiveness can be expected and under which circumstances. This makes it possible to approach the important phase of clinical research in a more targeted and faster way.
Significant market potential for anti-cancer drugs
Kummer continues: “Global sales of innovative cancer drugs and contract research for drug development present enormous economic opportunities for the Netherlands. Dutch knowledge institutions and (SME) companies will have access to the expertise and facilities offered by Oncode-PACT and will be able to go through the preclinical development process faster and more effectively. This way, Oncode-PACT will create new business, knowledge and technology in drug development and contract research, strengthen the business climate for foreign companies and develop affordable cancer treatments.”
Impact on patients
The way of working within Oncode-PACT ensures that patients receive more viable treatments as early as possible. Thanks to this new way of drug development, it will be possible in the future to offer tailor-made treatment at a much earlier stage of a patient’s disease and make a difference that way.
“The quality of the science captured in Oncode-PACT is clearly outstanding. We are excited and proud to be working as part of the Oncode-PACT consortium to bring breakthrough scientific discoveries from one of the world-leading biopharma ecosystems to patients faster and more efficiently,” commented Erik Manting, PhD, Chief Executive Officer of Immunicum. “Within the Oncode-PACT consortium, Immunicum will continue to leverage its expertise in dendritic cell biology to design novel cancer immunotherapies, including the combination with other cell-based therapies.”
Oncode-PACT is a unique national consortium of public and private partners, in which Oncode Institute is the lead party. Within Oncode-PACT, researchers, oncologists, knowledge institutes and the business community work together to develop better and affordable cancer medicines more quickly. There is close coordination with the Ministry of EZK (applicant) and the Ministry of Health, Welfare and Sport. In addition to the planned own investment by the Oncode-PACT partners, a contribution has been requested from the National Growth Fund to be able to realize the national plan. See also http://www.oncode.nl/Oncode-PACT
About the National Growth Fund
With the National Growth Fund, the government will invest 20 billion euros between 2021 and 2025 in projects that ensure long-term structural and sustainable economic growth. It concerns projects in the field of research, development and innovation in the areas where the Netherlands has the most opportunities
All submitted projects are carefully assessed by an independent committee against specific criteria. In the event of a positive recommendation from the committee, the cabinet decides whether money will be allocated immediately or whether money will be reserved for a project. In the case of a reservation, a better substantiation will be requested, after which the project will be reassessed by the committee.
More information about the National Growth Fund and the investment proposals of projects can be found at www.nationaalgroeifonds.nl
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Executive Officer
Stern Investor Relations
Telephone: +1 212-698-8695
Telephone: +49 160 9352 9951
ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for blood-borne and solid tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Vapers deliver an open letter to Swedish Members of the Parliament and ask to stop the vaping flavour ban25.5.2022 09:10:17 CEST | Press release
Stockholm, Sweden, May 25, 2022 (GLOBE NEWSWIRE) -- Yesterday, the global vaping advocacy group World Vapers Alliance delivered an open letter to the Swedish parliament urging policymakers to stop the flavour ban. World Vapers’ Alliance held another protest today to stand against the ban on vape flavours. The group marched in front of the Parliament with the slogan “Flavours help smokers quit” during parliament's session and delivered an open letter to members of parliament to urge them to vote against the ban. Earlier this year, the Swedish government introduced a bill that would prohibit all non-tobacco vape flavours in nicotine and non-nicotine products. If approved, the bill is set to enter into force on 1 January 2023. “I benefited first hand from vaping and managed to stay smoke free for the last few years. Like most other smokers, I tried to find a way out of cigarettes - but nothing worked for me, the patches, the gums, the inhalers. Vaping - and especially combined with flavou
Kalera - Last day of trading in Kalera AS' shares on Euronext Growth Oslo25.5.2022 08:00:00 CEST | Press release
OSLO, Norway, May 25, 2022 (GLOBE NEWSWIRE) -- Reference is made to the stock exchange announcement published by Kalera AS (the "Company") (Euronext Growth Oslo: KAL, Bloomberg: KSLLF) on 13 May 2022 regarding the merger with its wholly-owned Luxembourg subsidiary Kalera S.A. (the "Merger"). The Merger will become effective upon publication of the minutes from Kalera S.A.'s general meeting approving the Merger in accordance with Luxembourg law. Such publication, and the effectiveness of the Merger, is expected to occur on 27 May 2022 (the "Effectiveness"). The last day of trading in the Company's shares on Euronext Growth Oslo is today, 25 May 2022. A trading suspension will be imposed by the Oslo Stock Exchange following end of trading today, and the trading suspension will remain in force until the Effectiveness. As of the Effectiveness, all of the Company's assets, rights and liabilities will be transferred to Kalera S.A., and the Company will be dissolved and have it shares deliste
Reminder of an Investor Conference Webinar25.5.2022 08:00:00 CEST | Press release
We would like to remind that KN invites shareholders, investors, analysts, and other stakeholders to join its investor conference webinar scheduled on May 27th of 2022 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and Chief Financial Officer Mindaugas Kvekšas who will introduce the performance and unaudited financial results of KN for the three months of 2022. How to join the webinar? To join the webinar, please register via following link: https://nasdaq.zoom.us/webinar/register/WN_aVz8e35rRqO1UC5O3WBp4AYou will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to register on the Zoom platform. The webinar will be recorded and available online for everyone at the company’s website on www.kn.lt and on Nasdaq Baltic youtube.com account. What is a corporate webinar? A corporate webinar is a virtual conference, du
Saniona publishes its interim report for the first quarter of 202225.5.2022 08:00:00 CEST | Press release
Q12022 (Q12021) Revenue was SEK 6.6 M (3.4 M)Operating loss was SEK -133.2 M (-94.1 M) Net loss was SEK -133.4 M (-83.4 M)Loss per share was SEK -2.14 (-1.34)Diluted loss per share was SEK -2.14 (-1.34) Business highlights in Q1 2022 Saniona initiated the Multiple Ascending Dose (MAD) stage and the Positron Emission Tomography (PET) stage of its Phase 1 trial of SAN711; The ongoing Phase 1 trial is placebo-controlled, and the data remain blinded. Saniona continues to expect data from the trial by mid-2022.Saniona received SEK 7.3 million (US$0.8 million) from Novartis related to Novartis’s January 2021 acquisition of Cadent Therapeutics, in which Saniona held a 3% ownership stake. This payment, in addition to the previously received SEK 24.2 million (US$2.9 million), together complete Saniona’s portion of the upfront payment connected to the acquisition. Saniona may also receive a portion of the remaining SEK 5.1 billion (US$560 million) in contingent payments associated with the achie
Saniona publicerar sin delårsrapport för det första kvartalet 202225.5.2022 08:00:00 CEST | Pressemelding
Q1 2022 (Q1 2021) Intäkter uppgick till 6,6 MSEK (3,4 M)Rörelseresultat uppgick till -133,2 MSEK (-94,1 M) Periodens resultat uppgick till -133,4 MSEK (-83,4 M)Resultat per aktie uppgick till -2,14 SEK (-1,34)Resultat per aktie efter utspädning uppgick till -2,14 SEK (-1,34) Väsentliga händelser under Q1 2022 Saniona inledde upprepad dosering med doseskalering (MAD) samt undersökningar med positronemissionstomografi (PET) i Fas 1-studien med SAN711; den pågående Fas 1-studien är placebokontrollerad och data är fortfarande blindade. Saniona räknar fortsatt med att få tillgång till data från studien under mitten av 2022.Saniona erhöll 7,3 MSEK (0,8 MUSD) från Novartis relaterat till Novartis förvärv av Cadent Therapeutics i januari 2021, där Saniona hade en ägarandel på 3 procent. Denna betalning, utöver de tidigare erhållna 24,2 MSEK (2,9 MUSD), utgör tillsammans Sanionas del av förskottsbetalningen kopplad till förvärvet. Saniona kan också komma att erhålla en andel av de återstående 5